Comprehensive review of targeted therapy for colorectal cancer
Open accessThe DOI matches its Crossref record; 521 of the 521 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have long been the first choices for cancer patients. However, the prognosis of CRC has never been satisfying, especially for patients with metastatic lesions. Targeted therapy is a new optional approach that has successfully prolonged overall survival for CRC patients. Following successes with the anti-EGFR (epidermal growth factor receptor) agent cetuximab and the anti-angiogenesis agent bevacizumab, new agents blocking different critical pathways as well as immune checkpoints are emerging at an unprecedented rate. Guidelines worldwide are currently updating the recommended targeted drugs on the basis of the increasing number of high-quality clinical trials. This review provides an overview of existing CRC-targeted agents and their underlying mechanisms, as well as a discussion of their limitations and future trends.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The therapeutic landscape of metastatic colorectal cancer is moving toward biomarker-selected strategies. However, options are limited to agents directed at tumors carrying BRAF V600E mutations and to antibodies against programmed death 1 (PD-1) in patients with high microsatellite instability or mismatch-repair deficiency.13,26,27”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current first-line standard of care for KRAS G12C-positive CRC includes 5-FU-based chemotherapy with irinotecan, oxaliplatin and/or capecitabine, but is limited by low tumor-specific selectivity and systemic toxicity21.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Cetuximab is an anti-EGFR monoclonal antibody that is indicated for the treatment of RAS wild-type metastatic colorectal cancer, either as monotherapy or in combination with chemotherapy.13”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Currently, no therapies that specifically target KRAS G12C protein have been approved for the treatment of colorectal cancer.13,19”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“ROS-mediated DNA damage induces p53 phosphorylation, which in turn stabilizes p53, indispensable to counter tumorigenic growth and differentiation.68”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Lee, Y., Karl, D. L., Maduekwe, U. N., Rothrock, C., Ryeom, S. W., D'Amore, P. A., & Yoon, S. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1138 · Cited by 69
RetractedYang, S., Zhang, X., Qu, H., Qu, B., Yin, X., & Zhao, H. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0098-6 · Cited by 16 · cited 1×
“Similarly, an exciting antitumor performance of cabozantinib was observed in research based on CRC xenograft models and cell lines, while the results from CRC-focused clinical trials are awaited.(289,336,337) Merestinib, an inhibitor of MET, AXL (Axl receptor tyrosine kinase), TEK (tunica interna endothelial cell kina…”
BackgroundRetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cited by
Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920
“Because of the increasing effectiveness of treatments such as the anti-EGFR (epidermal growth factor receptor) agent cetuximab and the anti-angiogenesis agent bevacizumab are innovative medications that inhibit numerous immunological pathways checkpoints are being developed at an unprecedented rate [106].”
BackgroundInfluentialSingh, V., Lee, G., Son, H., Koh, H., Kim, E. S., Unno, T., & Shin, J.-H. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1103836 · Cited by 705
“Evidence has shown that alterations in the gut microbiota are closely associated with CRC progression (Xie et al., 2020).”
BackgroundMetastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 669
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Metadata
- Authors
- Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Fang, Jing-Yuan
- ORCID
- Fang, Jing-Yuan
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2020-03-20
- Volume
- 5
- Issue
- 1
- Pages
- 22-22
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC7082344
- OpenAlex
- W3011481749
- Semantic Scholar
- 4980bbd78186d8dcd72cea78c224da6b545d763a
- Cited by
- 1,687
- References
- 521
- Citations by year
- 2026: 153 · 2025: 285 · 2024: 348 · 2023: 346 · 2022: 300 · 2021: 202 · 2020: 51
- FWCI
- 24.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81421001, 81530072)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- colorectal cancer, targeted therapy, metastatic colorectal cancer, anti-EGFR therapy, cetuximab, bevacizumab, angiogenesis inhibitors, immune checkpoint inhibitors, molecular pathways, drug mechanisms, treatment guidelines
- MeSH terms
- Bevacizumab, Cetuximab, Humans, Neoplasm Metastasis, Neovascularization, Pathologic, Colorectal Neoplasms, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive review of targeted therapy for colorectal cancer. https://app.cochat.ai/papers/10.1038/s41392-020-0116-z
- The paper
- Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020). Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-0116-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.